Regenerative medicine group Orthocell (ASX:OCC) has appointed LEDA Orthopaedics as the exclusive distributor for its flagship collagen nerve wrap, Remplir, across the United Kingdom.
The partnership arrives as Orthocell prepares to penetrate the lucrative British market, following a regulatory submission to the British Standards Institution in late 2025.
With approval anticipated by the end of the year, LEDA is set to deploy a specialised team of over 40 direct sales representatives and a dedicated biologics business development manager to spearhead the product’s commercial debut.
The UK and European Union represent a combined US$750 million market opportunity, where approximately 500,000 peripheral nerve repairs are performed annually.
LEDA’s extensive experience in upper limb and reconstructive procedures provides Orthocell with immediate access to a vast network of orthopaedic and plastic surgeons.
Orthocell CEO Paul Anderson noted that appointing a distributor ahead of formal clearance allows for essential market preparation, including surgeon education and hospital procurement planning, to ensure a rapid clinical uptake upon launch.
The expansion is underpinned by a robust balance sheet, with Orthocell reporting $49.4 million in cash reserves to fund its global ambitions.
Remplir is already gaining clinical traction in Australia, the US, and Singapore, with Canadian sales expected later this year.
LEDA co-founder David Plane expressed enthusiasm for the collaboration, citing a shared commitment to excellence in nerve repair technology.
At the time of reporting, Orthocell’s share price was $0.82.